A Comprehensive Overview of the Role of the RET Proto-oncogene in Thyroid Carcinoma

Overview

Journal Nat Rev Endocrinol

Specialty Endocrinology

Date 2016 Feb 13

PMID 26868437

Citations 144

Authors

Cristina Romei

Raffaele Ciampi

Rossella Elisei

Affiliations

Soon will be listed here.

Abstract

The rearranged during transfection (RET) proto-oncogene was identified in 1985 and, very soon thereafter, a rearrangement named RET/PTC was discovered in papillary thyroid carcinoma (PTC). After this discovery, other RET rearrangements were found in PTCs, particularly in those induced by radiation. For many years, it was thought that these genetic alterations only occurred in PTC, but, in the past couple of years, some RET/PTC rearrangements have been found in other human tumours. 5 years after the discovery of RET/PTC rearrangements in PTC, activating point mutations in the RET proto-oncogene were discovered in both hereditary and sporadic forms of medullary thyroid carcinoma (MTC). In contrast to the alterations found in PTC, the activation of RET in MTC is mainly due to activating point mutations. Interestingly, in the past year, RET rearrangements that were different to those described in PTC were observed in sporadic MTC. The identification of RET mutations is relevant to the early diagnosis of hereditary MTC and the prognosis of sporadic MTC. The diagnostic and prognostic role of the RET/PTC rearrangements in PTC is less relevant but still important in patient management, particularly for deciding if a targeted therapy should be initiated. In this Review, we discuss the pathogenic, diagnostic and prognostic roles of the RET proto-oncogene in both PTC and MTC.

Citing Articles

Neuroendocrine Tumors: Germline Genetics and Hereditary Syndromes.

Lauricella E, Chaoul N, DAngelo G, Giglio A, Cafiero C, Porta C Curr Treat Options Oncol. 2025; 26(1):55-71.

PMID: 39821711 DOI: 10.1007/s11864-024-01288-z.

A novel role for nonactin: interfering with G-quadruplex in RET-driven medullary thyroid cancer.

Alqahtani T, Alsubait A, Aloumi M, Alamer A, Alomari G, Alwassil O BMC Cancer. 2024; 24(1):1569.

PMID: 39716145 PMC: 11665027. DOI: 10.1186/s12885-024-13345-9.

Pathogenesis and Management Strategies in Radioiodine-Refractory Differentiated Thyroid Cancer: From Molecular Mechanisms Toward Therapeutic Approaches: A Comprehensive Review.

Voinea I, Petrova E, Dumitru N, Cocolos A, Ioachim D, Goldstein A J Clin Med. 2024; 13(23).

PMID: 39685621 PMC: 11641973. DOI: 10.3390/jcm13237161.

Mechanisms of resistance to RET-directed therapies.

Clifton-Bligh R Endocr Relat Cancer. 2024; 32(2).

PMID: 39655713 PMC: 11798414. DOI: 10.1530/ERC-24-0224.

First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors.

Li W, Wang Y, Xiong A, Gao G, Song Z, Zhang Y Signal Transduct Target Ther. 2024; 9(1):300.

PMID: 39489747 PMC: 11532403. DOI: 10.1038/s41392-024-02006-9.

References

Klugbauer S, Jauch A, Lengfelder E, Demidchik E, Rabes H . A novel type of RET rearrangement (PTC8) in childhood papillary thyroid carcinomas and characterization of the involved gene (RFG8). Cancer Res. 2001; 60(24):7028-32. View

Lodish M, Stratakis C . RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer. Expert Rev Anticancer Ther. 2008; 8(4):625-32. PMC: 2670186. DOI: 10.1586/14737140.8.4.625. View

Wells Jr S, Asa S, Dralle H, Elisei R, Evans D, Gagel R . Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015; 25(6):567-610. PMC: 4490627. DOI: 10.1089/thy.2014.0335. View

Romei C, Ugolini C, Cosci B, Torregrossa L, Vivaldi A, Ciampi R . Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer. Thyroid. 2012; 22(5):476-81. DOI: 10.1089/thy.2011.0358. View

Klugbauer S, Demidchik E, Lengfelder E, Rabes H . Detection of a novel type of RET rearrangement (PTC5) in thyroid carcinomas after Chernobyl and analysis of the involved RET-fused gene RFG5. Cancer Res. 1998; 58(2):198-203. View

Takahashi M, Ritz J, Cooper G . Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell. 1985; 42(2):581-8. DOI: 10.1016/0092-8674(85)90115-1. View

Fusco A, Grieco M, Santoro M, Berlingieri M, Pilotti S, Pierotti M . A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature. 1987; 328(6126):170-2. DOI: 10.1038/328170a0. View

Klein Hesselink E, Steenvoorden D, Kapiteijn E, Corssmit E, van der Horst-Schrivers A, Lefrandt J . Therapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis. Eur J Endocrinol. 2015; 172(5):R215-25. DOI: 10.1530/EJE-14-0788. View

Elisei R, Cosci B, Romei C, Agate L, Piampiani P, Miccoli P . Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition. J Clin Endocrinol Metab. 2004; 89(11):5823-7. DOI: 10.1210/jc.2004-0312. View

10.

Nikiforov Y, Rowland J, Bove K, Fagin J . Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 1997; 57(9):1690-4. View

11.

Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E . RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab. 2007; 92(12):4725-9. DOI: 10.1210/jc.2007-1005. View

12.

Russo R, Trippi D, Falaschi F, Orsitto E, Cioni R, Elisei R . [MEN IIB. A case report]. Radiol Med. 1994; 87(1-2):168-71. View

13.

Sheils O, Oeary J, Uhlmann V, Lattich K, Sweeney E . ret/PTC-1 Activation in Hashimoto Thyroiditis. Int J Surg Pathol. 2001; 8(3):185-189. DOI: 10.1177/106689690000800305. View

14.

Lira M, Choi Y, Lim S, Deng S, Huang D, Ozeck M . A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer. J Mol Diagn. 2014; 16(2):229-43. DOI: 10.1016/j.jmoldx.2013.11.007. View

15.

Orgiana G, Pinna G, Camedda A, De Falco V, Santoro M, Melillo R . A new germline RET mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thyroiditis and primary ovarian failure. J Clin Endocrinol Metab. 2004; 89(10):4810-6. DOI: 10.1210/jc.2004-0365. View

16.

Schuchardt A, DAgati V, Costantini F, Pachnis V . Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature. 1994; 367(6461):380-3. DOI: 10.1038/367380a0. View

17.

Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R . Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013; 2013:965212. PMC: 3664492. DOI: 10.1155/2013/965212. View

18.

Klugbauer S, Rabes H . The transcription coactivator HTIF1 and a related protein are fused to the RET receptor tyrosine kinase in childhood papillary thyroid carcinomas. Oncogene. 1999; 18(30):4388-93. DOI: 10.1038/sj.onc.1202824. View

19.

Machens A, Hauptmann S, Dralle H . Modification of multiple endocrine neoplasia 2A phenotype by cell membrane proximity of RET mutations in exon 10. Endocr Relat Cancer. 2008; 16(1):171-7. DOI: 10.1677/ERC-08-0096. View

20.

. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014; 159(3):676-90. PMC: 4243044. DOI: 10.1016/j.cell.2014.09.050. View